Cell MedX Corp. (OTCMKTS:CMXC – Get Free Report) traded down 6% on Thursday . The stock traded as low as $0.47 and last traded at $0.47. 500 shares traded hands during trading, a decline of 98% from the average session volume of 20,342 shares. The stock had previously closed at $0.50.
Cell MedX Stock Down 6.0 %
The stock has a 50 day simple moving average of $0.33 and a 200-day simple moving average of $0.13.
Cell MedX Company Profile
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney functions in the United States. The company develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual.
Recommended Stories
- Five stocks we like better than Cell MedX
- What is the Nasdaq? Complete Overview with History
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- 10 Best Airline Stocks to Buy
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- What is a SEC Filing?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Cell MedX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cell MedX and related companies with MarketBeat.com's FREE daily email newsletter.